Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Phase 2 Study of LY3471851 in Moderately to Severely Active Ulcerative Colitis
jRCT2031200403Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LY3471851 with Placebo (2 arms). Primary endpoint: Percentage of participants in clinical remission at Week 12. Started Mar 2021; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031200403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200403.